Expert Perspectives on the Clinical Use of Immune Reconstitution vs Escalation Therapy for MS

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Disease-Modifying Treatments for MS

Evolving Therapeutic Landscape in MS

Maintenance/Escalation Therapy vs IRT

Predictors of Disability Disease Factors

Predictors of Disability Patient Factors

Predictors of Disability: Imaging

Neurofilament Levels as Markers of Disease Activity

Benefit of Early Treatment Initiation

Monitoring Burden With DMT

Case Study 1

Case Study 1 Workup

Case Study 1: Treatment Considerations

Pregnancy Considerations With DMT Use

Reduced Risk of CIS Conversion to CDMS With Cladribine

Case Study 2

Case Study 2 MRI Findings

Case Study 2 Treatment Considerations

Case Study 3

Case Study 3 Workup Postpartum

Case Study 3 Treatment Considerations

Case Study 3 Potential Role for IVIG?

Conclusions

Abbreviations

Abbreviations (cont)

Abbreviations (cont)